Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IBIO - iBio Inc


Close
1.97
0.100   5.076%

Share volume: 32,889
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.87
0.10
5.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
14%
Profitability 0%
Dept financing 18%
Liquidity 50%
Performance 17%
Company vs Stock growth
vs
Performance
5 Days
-2.96%
1 Month
-4.37%
3 Months
-11.66%
6 Months
62.81%
1 Year
-68.22%
2 Year
-98.60%
Key data
Stock price
$1.97
P/E Ratio 
0.00
DAY RANGE
$1.85 - $1.97
EPS 
$0.00
52 WEEK RANGE
$1.02 - $8.57
52 WEEK CHANGE
-$0.66
MARKET CAP 
16.989 M
YIELD 
N/A
SHARES OUTSTANDING 
8.624 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$54,052
AVERAGE 30 VOLUME 
$84,719
Company detail
CEO:
Region: US
Website: ibioinc.com
Employees: 117
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.

Recent news